HUE033531T2 - Combination therapy of an afucosylated cd20 antibody with bendamustine - Google Patents

Combination therapy of an afucosylated cd20 antibody with bendamustine

Info

Publication number: HUE033531T2
Authority: HU; Hungary
Prior art keywords: afucosylated; bendamustine; antibody; combination therapy; therapy
Prior art date: 2009-08-14

Application number

HUE10747168A

Other languages

Hungarian (hu)

Inventor

Frank Herting

Christian Klein

Original Assignee

Roche Glycart Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-14

Filing date

2010-08-12

Publication date

2021-12-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033531(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-08-12 Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag

2021-12-28 Publication of HUE033531T2 publication Critical patent/HUE033531T2/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HUE10747168A 2009-08-14 2010-08-12 Combination therapy of an afucosylated cd20 antibody with bendamustine HUE033531T2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09010489		2009-08-14

Publications (1)

Publication Number	Publication Date
HUE033531T2 true HUE033531T2 (en)	2021-12-28

Family

ID=41351729

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE10747168A HUE033531T2 (en)	2009-08-14	2010-08-12	Combination therapy of an afucosylated cd20 antibody with bendamustine
HUS1700041C HUS000498I2 (en)	2009-08-14	2017-10-27	Obinutuzumab in combination with bendamustine

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HUS1700041C HUS000498I2 (en)	2009-08-14	2017-10-27	Obinutuzumab in combination with bendamustine

Country Status (34)

Country	Link
US (4)	US20110165151A1 (en)
EP (1)	EP2464382B1 (en)
JP (3)	JP5646626B2 (en)
KR (1)	KR101425736B1 (en)
CN (2)	CN102596245A (en)
AR (1)	AR077866A1 (en)
AU (1)	AU2010281866B2 (en)
CA (1)	CA2769674C (en)
CL (1)	CL2012000391A1 (en)
CR (1)	CR20120036A (en)
CY (2)	CY1119251T1 (en)
DK (1)	DK2464382T3 (en)
ES (1)	ES2630158T3 (en)
HK (1)	HK1245145A1 (en)
HR (1)	HRP20170972T1 (en)
HU (2)	HUE033531T2 (en)
IL (1)	IL217753A (en)
LT (2)	LT2464382T (en)
LU (1)	LUC00045I2 (en)
MA (1)	MA33469B1 (en)
MX (2)	MX355849B (en)
MY (1)	MY163003A (en)
NO (1)	NO2017054I1 (en)
NZ (1)	NZ597666A (en)
PL (1)	PL2464382T3 (en)
PT (1)	PT2464382T (en)
RS (1)	RS56146B1 (en)
SG (1)	SG178324A1 (en)
SI (1)	SI2464382T1 (en)
SM (1)	SMT201700329T1 (en)
TW (1)	TWI409079B (en)
UA (1)	UA110096C2 (en)
WO (1)	WO2011018224A1 (en)
ZA (1)	ZA201200830B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0416262B1 (en)	2003-11-05	2022-04-12	Roche Glycart Ag	Humanized type II anti-human cd20 antibody, its production method, its uses, as well as isolated polynucleotide, expression vector and pharmaceutical composition
EP2641618A3 (en)	2007-07-16	2013-10-23	Genentech, Inc.	Humanized anti-CD79B antibodies and immunoconjugates and methods of use
CL2008002085A1 (en)	2007-07-16	2008-11-21	Genentech Inc	Humanized anti-cd79b / igbeta / b29 antibody; coding polynucleotide, vector, host cell; manufacturing method; immunoconjugate; pharmaceutical composition; use to treat cancer; in vitro method to determine the presence of cd79b, or inhibit growth of quqe cells expressing cd79b; in vitro assay to detect b cells
CN104650230A (en)	2008-01-31	2015-05-27	健泰科生物技术公司	Anti-CD79B antibodies and immunoconjugates and methods of use
MY169745A (en)	2010-05-31	2019-05-14	Ono Pharmaceutical Co	Purinone derivative
FR2976811A1 (en) *	2011-06-22	2012-12-28	Lfb Biotechnologies	USE OF A HIGH ADCC ANTI-CD20 ANTIBODY FOR THE TREATMENT OF WALDENSTROM'S DISEASE
PL2744826T3 (en) *	2011-08-16	2022-05-30	Morphosys Ag	Combination therapy with an anti-cd19 antibody and a purine analog
KR20200058583A (en) *	2011-08-16	2020-05-27	모르포시스 아게	Combination therapy with an anti-cd19 antibody and a nitrogen mustard
FR2980110A1 (en) *	2011-09-20	2013-03-22	Lfb Biotechnologies	Composition, useful for treating tumor including malignant tumor, leukemia and non-Hodgkin lymphoma, comprises bendamustine and an anti-cluster of differentiation 20 antibody, which is a monoclonal antibody
NZ626750A (en)	2011-11-29	2015-08-28	Ono Pharmaceutical Co	Purinone derivative hydrochloride
CN103375132A (en) *	2012-04-24	2013-10-30	长江大学	Down-hole rotary impact type drilling tool
JP2016507523A (en)	2013-02-05	2016-03-10	エンクマフアーゲー	Bispecific antibodies against CD3ε and BCMA
EP2762496A1 (en)	2013-02-05	2014-08-06	EngMab AG	Method for the selection of antibodies against BCMA
US20160101199A1 (en)	2013-06-07	2016-04-14	Nordic Nanovector As	Method for upregulating antigen expression
WO2015146159A1 (en)	2014-03-25	2015-10-01	Ono Pharmaceutical Co., Ltd.	Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
EP3262071B8 (en)	2014-09-23	2022-05-18	F. Hoffmann-La Roche AG	Method of using anti-cd79b immunoconjugates
WO2016163531A1 (en)	2015-04-09	2016-10-13	小野薬品工業株式会社	Process for producing purinone derivative
CN108350073B (en)	2015-08-03	2022-03-18	英格玛布有限责任公司	Monoclonal antibodies against BCMA
EP3257866A1 (en) *	2016-06-17	2017-12-20	Academisch Medisch Centrum	Modified anti-tnf antibody and use thereof in the treatment of ibd
EP4295918A3 (en)	2016-11-02	2024-03-20	Bristol-Myers Squibb Company	Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
WO2018106931A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en)	2017-03-30	2018-10-04	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
SG11202011545YA (en)	2018-05-23	2020-12-30	Celgene Corp	Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en)	2018-06-20	2025-02-18	Biora Therapeutics, Inc.	Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN116726361A (en)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	Methods and devices for treating diseases with biologic therapeutic agents
JP7287048B2 (en)	2019-03-27	2023-06-06	セイコーエプソン株式会社	robot
US11707610B2 (en)	2019-12-13	2023-07-25	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
DK1071700T3 (en)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
HK1040720A1 (en)	1998-05-15	2002-06-21	伊姆克罗尼系统公司	Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
AU3672800A (en)	1999-04-09	2000-11-14	Kyowa Hakko Kogyo Co. Ltd.	Method for controlling the activity of immunologically functional molecule
FR2807767B1 (en)	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	MONOCLONAL ANTIBODIES ANTI-D
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ATE430580T1 (en)	2001-10-25	2009-05-15	Genentech Inc	GLYCOPROTEIN COMPOSITIONS
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
KR100932340B1 (en)	2002-10-17	2009-12-16	젠맵 에이/에스	Human monoclonal antibodies against CD20
CN103833854B (en)	2002-12-16	2017-12-12	健泰科生物技术公司	Immunoglobulin variants and application thereof
PL222220B1 (en)	2003-01-22	2016-07-29	Glycart Biotechnology Ag	Host cell, method for producing a polypeptide in a host cell, antibody, antibody fragment, protein fusion, a pharmaceutical composition and method for treating cancer
EP1628531A4 (en) *	2003-05-16	2010-06-30	Idera Pharmaceuticals Inc	Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
JP2007500508A (en)	2003-07-29	2007-01-18	モルフォテック、インク．	Methods for producing recombinant antibodies with enhanced antibody and effector functions
WO2005018572A2 (en)	2003-08-22	2005-03-03	Biogen Idec Ma Inc.	Improved antibodies having altered effector function and methods for making the same
AU2004273791A1 (en)	2003-09-05	2005-03-31	Genentech, Inc.	Antibodies with altered effector functions
BRPI0416262B1 (en) *	2003-11-05	2022-04-12	Roche Glycart Ag	Humanized type II anti-human cd20 antibody, its production method, its uses, as well as isolated polynucleotide, expression vector and pharmaceutical composition
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
CA2587766A1 (en)	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
CA2605697A1 (en)	2005-04-26	2006-11-02	Bioren, Inc.	Method of producing human igg antibodies with enhanced effector functions
JP5255435B2 (en)	2005-04-26	2013-08-07	メディミューン，エルエルシー	Regulation of antibody effector function by hinge domain manipulation
KR101460932B1 (en)	2005-08-26	2014-11-12	로슈 글리카트 아게	Modified antigen binding molecules with altered cell signaling activity
KR101507027B1 (en) *	2005-10-21	2015-03-31	엘에프비 유에스에이, 인크.	Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) *	2007-10-24	2009-04-30	Georg Fertig	Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
US8802089B2 (en) *	2008-01-03	2014-08-12	Genmab A/S	Monoclonal antibodies against CD32B
EA201170940A1 (en) *	2009-01-16	2012-02-28	ГЛЭКСОСМИТКЛАЙН ЭлЭлСи	CANCER TREATMENT USING BENDAMUSTIN AND ANTI-CD20-ANTIBODY COMBINATION
WO2010120288A1 (en) *	2009-04-15	2010-10-21	Invista Technologies S.A R.L.	Improving miscibility of otherwise immiscible compounds

2010
- 2010-08-11 TW TW099126813A patent/TWI409079B/en active
- 2010-08-12 EP EP10747168.2A patent/EP2464382B1/en active Active
- 2010-08-12 CN CN201080035971XA patent/CN102596245A/en active Pending
- 2010-08-12 CA CA2769674A patent/CA2769674C/en active Active
- 2010-08-12 ES ES10747168.2T patent/ES2630158T3/en active Active
- 2010-08-12 SM SM20170329T patent/SMT201700329T1/en unknown
- 2010-08-12 MY MYPI2012000606A patent/MY163003A/en unknown
- 2010-08-12 HU HUE10747168A patent/HUE033531T2/en unknown
- 2010-08-12 CN CN201710422477.2A patent/CN107261138A/en active Pending
- 2010-08-12 AU AU2010281866A patent/AU2010281866B2/en active Active
- 2010-08-12 HR HRP20170972TT patent/HRP20170972T1/en unknown
- 2010-08-12 NZ NZ597666A patent/NZ597666A/en unknown
- 2010-08-12 MA MA34585A patent/MA33469B1/en unknown
- 2010-08-12 PT PT107471682T patent/PT2464382T/en unknown
- 2010-08-12 AR ARP100102968A patent/AR077866A1/en unknown
- 2010-08-12 PL PL10747168T patent/PL2464382T3/en unknown
- 2010-08-12 MX MX2014015198A patent/MX355849B/en unknown
- 2010-08-12 LT LTEP10747168.2T patent/LT2464382T/en unknown
- 2010-08-12 KR KR1020127006528A patent/KR101425736B1/en active Active
- 2010-08-12 JP JP2012524146A patent/JP5646626B2/en active Active
- 2010-08-12 DK DK10747168.2T patent/DK2464382T3/en active
- 2010-08-12 SG SG2012008843A patent/SG178324A1/en unknown
- 2010-08-12 MX MX2012001782A patent/MX2012001782A/en active IP Right Grant
- 2010-08-12 SI SI201031491T patent/SI2464382T1/en unknown
- 2010-08-12 RS RS20170647A patent/RS56146B1/en unknown
- 2010-08-12 WO PCT/EP2010/004939 patent/WO2011018224A1/en not_active Ceased
- 2010-08-13 US US12/855,827 patent/US20110165151A1/en not_active Abandoned
- 2010-12-08 UA UAA201202678A patent/UA110096C2/en unknown
2012
- 2012-01-19 CR CR20120036A patent/CR20120036A/en unknown
- 2012-01-26 IL IL217753A patent/IL217753A/en active IP Right Grant
- 2012-02-02 ZA ZA2012/00830A patent/ZA201200830B/en unknown
- 2012-02-08 US US13/368,465 patent/US20120315268A1/en not_active Abandoned
- 2012-02-14 CL CL2012000391A patent/CL2012000391A1/en unknown
2013
- 2013-01-18 HK HK18104879.8A patent/HK1245145A1/en unknown
- 2013-03-06 US US13/787,532 patent/US20140044705A1/en not_active Abandoned
2014
- 2014-05-08 US US14/273,148 patent/US20160166688A9/en not_active Abandoned
- 2014-11-04 JP JP2014224221A patent/JP5963013B2/en active Active
2016
- 2016-06-15 JP JP2016118739A patent/JP2016222673A/en active Pending
2017
- 2017-07-03 CY CY20171100706T patent/CY1119251T1/en unknown
- 2017-10-26 LU LU00045C patent/LUC00045I2/fr unknown
- 2017-10-26 NO NO2017054C patent/NO2017054I1/en unknown
- 2017-10-26 CY CY2017034C patent/CY2017034I1/en unknown
- 2017-10-27 HU HUS1700041C patent/HUS000498I2/en unknown
- 2017-10-31 LT LTPA2017035C patent/LTPA2017035I1/en unknown

Also Published As

Publication number	Publication date
PL2464382T3 (en)	2017-09-29
MX2012001782A (en)	2012-04-19
JP5646626B2 (en)	2014-12-24
MY163003A (en)	2017-07-31
IL217753A (en)	2016-10-31
CL2012000391A1 (en)	2012-08-24
TWI409079B (en)	2013-09-21
TW201110980A (en)	2011-04-01
AR077866A1 (en)	2011-09-28
AU2010281866B2 (en)	2016-05-12
SG178324A1 (en)	2012-03-29
MX355849B (en)	2018-05-02
CY2017034I2 (en)	2018-02-14
AU2010281866A1 (en)	2012-02-02
CY1119251T1 (en)	2018-02-14
ZA201200830B (en)	2012-10-31
KR20120054068A (en)	2012-05-29
EP2464382B1 (en)	2017-05-03
HUS1700041I1 (en)	2017-11-28
WO2011018224A1 (en)	2011-02-17
NZ597666A (en)	2013-10-25
CA2769674C (en)	2018-01-23
NO2017054I1 (en)	2017-10-26
HK1245145A1 (en)	2018-08-24
SI2464382T1 (en)	2017-08-31
US20110165151A1 (en)	2011-07-07
LUC00045I1 (en)	2017-11-03
UA110096C2 (en)	2015-11-25
IL217753A0 (en)	2012-03-29
ES2630158T3 (en)	2017-08-18
HUS000498I2 (en)	2021-03-29
CN107261138A (en)	2017-10-20
JP2016222673A (en)	2016-12-28
MA33469B1 (en)	2012-07-03
KR101425736B1 (en)	2014-08-01
PT2464382T (en)	2017-06-30
HRP20170972T1 (en)	2017-09-22
BR112012002855A2 (en)	2016-11-01
JP2013501740A (en)	2013-01-17
CA2769674A1 (en)	2011-02-17
LT2464382T (en)	2017-07-25
CY2017034I1 (en)	2018-02-14
DK2464382T3 (en)	2017-07-17
RU2012109445A (en)	2013-09-27
US20160166688A9 (en)	2016-06-16
JP5963013B2 (en)	2016-08-03
JP2015071611A (en)	2015-04-16
CN102596245A (en)	2012-07-18
LUC00045I2 (en)	2018-02-26
US20140044705A1 (en)	2014-02-13
US20120315268A1 (en)	2012-12-13
LTPA2017035I1 (en)	2017-11-27
EP2464382A1 (en)	2012-06-20
SMT201700329T1 (en)	2017-09-07
RS56146B1 (en)	2017-11-30
US20150093376A1 (en)	2015-04-02
CR20120036A (en)	2012-04-18

Publication	Publication Date	Title
ZA201200830B (en)	2012-10-31	Combination therapy of an afucosylated cd20 antibody with bendamustine
HRP20190554T1 (en)	2019-05-03	Combination therapy with an antitumor alkaloid
EP2405937A4 (en)	2012-06-20	Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
EP2422846A4 (en)	2012-10-03	PARTICLE RADIATION THERAPY DEVICE
EP2534178A4 (en)	2013-08-07	Therapeutic methods using an ti-cd200 antibodies
PL2440287T3 (en)	2013-12-31	Device for photodynamic therapy
IL218724A0 (en)	2012-06-28	Endoglin antibodies
EP2590573A4 (en)	2015-06-03	An internal retractor
GB0900461D0 (en)	2009-02-11	Photodynamic therapy device
EP2618133A4 (en)	2014-12-03	Optical-electric-field enhancement device
IL213269A0 (en)	2011-07-31	Solid dosage forms of bendamustine
ZA201201038B (en)	2012-10-31	Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
IL215481A0 (en)	2011-12-29	Improved glucocorticoid therapy
EP2652507A4 (en)	2015-04-22	Detecting cancer with anti-ccl25 and anti-ccr9 antibodies
GB0905972D0 (en)	2009-05-20	Antibodies against IL-17BR
GB2471750B (en)	2012-02-08	Radiation therapy device
DK2325510T3 (en)	2013-06-03	Coupling with an annular coupling body
PL2100692T5 (en)	2018-10-31	Processing device with body made of concrete
GB0902916D0 (en)	2009-04-08	Antibody therapy
GB201008945D0 (en)	2010-07-14	An injector
GB2470001A9 (en)	2010-12-22	The reason of all cancer types
TWM385713U (en)	2010-08-01	Light source body structure